RÉSUMÉ
An appreciation of the contribution of Professor Gary Graham to anti-inflammatory and antirheumatic pharmacology and clinical pharmacology.
Sujet(s)
Anti-inflammatoires/pharmacologie , Antirhumatismaux/pharmacologie , Pharmacologie clinique/histoire , Anti-inflammatoires/histoire , Antirhumatismaux/histoire , Histoire du 20ème siècle , Histoire du 21ème siècle , HumainsRÉSUMÉ
Seventy years ago, the first administration of cortisone in a patient with RA marked a milestone in the treatment of inflammatory diseases. However, the initial enthusiasm rapidly vanished as the administration of high doses for lengthy periods revealed worrisome adverse effects. It has taken several decades to overcome the (sometimes excessive) mistrust and to achieve a more differentiated evaluation of the benefit-risk profile and the adequate usage of glucocorticoids (GCs). Today, GCs remain indispensable for the treatment of many inflammatory conditions and their usefulness in RA as a disease-modifying low-dose co-medication is widely acknowledged. Recent studies show promising results concerning both traditional GCs and new formulations. Still, decades of relatively little scientific attention have resulted in a continuing lack of detailed evidence. Hence there is an ongoing need for further research regarding mechanisms of GC actions, the further optimization of treatment parameters for traditional GCs and new formulations.
Sujet(s)
Antirhumatismaux/usage thérapeutique , Cortisone/usage thérapeutique , Glucocorticoïdes/usage thérapeutique , Rhumatismes/traitement médicamenteux , Commémorations et événements particuliers , Antirhumatismaux/histoire , Cortisone/histoire , Glucocorticoïdes/histoire , Histoire du 20ème siècle , Humains , Rhumatismes/histoire , Appréciation des risquesSujet(s)
Antirhumatismaux/usage thérapeutique , Polyarthrite rhumatoïde/traitement médicamenteux , Antirhumatismaux/effets indésirables , Antirhumatismaux/histoire , Polyarthrite rhumatoïde/diagnostic , Polyarthrite rhumatoïde/épidémiologie , Polyarthrite rhumatoïde/histoire , Diffusion des innovations , Histoire du 20ème siècle , Histoire du 21ème siècle , Humains , Médecine de précision , Résultat thérapeutiqueRÉSUMÉ
This review highlights the story of how methotrexate (MTX), a drug discovered for the treatment of childhood leukemia, became the mainstay of treatment and the standard-of-care for rheumatoid arthritis (RA) and was also found useful for several additional related rheumatological diseases. As against several synthetic disease-modifying antirheumatic drugs (csDMARDs) for treating RA that were discovered serendipitously, the use of low-dose MTX (LD-MTX) was based on sound reasoning and astute observations made in the 1940s and 1950s. The difference between high-dose MTX (HD-MTX) used in the treatment of childhood leukaemia and other malignancies as against LD-MTX used in rheumatology is emphasized.
Sujet(s)
Antirhumatismaux/usage thérapeutique , Polyarthrite rhumatoïde/traitement médicamenteux , Découverte de médicament , Méthotrexate/usage thérapeutique , Rhumatologie , Animaux , Antimétabolites antinéoplasiques/usage thérapeutique , Antirhumatismaux/effets indésirables , Antirhumatismaux/histoire , Polyarthrite rhumatoïde/diagnostic , Polyarthrite rhumatoïde/histoire , Découverte de médicament/histoire , Histoire du 20ème siècle , Humains , Méthotrexate/effets indésirables , Méthotrexate/histoire , Rhumatologie/histoire , Résultat thérapeutiqueSujet(s)
Rhumatismes/histoire , Rhumatologie/histoire , Antirhumatismaux/histoire , Antirhumatismaux/usage thérapeutique , Prévision , Histoire du 19ème siècle , Histoire du 20ème siècle , Histoire du 21ème siècle , Histoire ancienne , Humains , Rhumatismes/diagnostic , Rhumatismes/thérapie , Rhumatologie/tendancesRÉSUMÉ
The use of immunosuppressive drugs in rheumatology is fairly recent, starting just after the Second World War with the introduction of the first alkylating agents in oncohematology. When it became clear that some rheumatic diseases, particularly rheumatoid arthritis and systemic lupus erythematosus, showed an immune-mediated pathogenesis, including proliferation of immunocompetent cells, an application was soon found for immunosuppressive drugs in their treatment. This review outlines the historical milestones that led to the current use of drugs belonging to the major groups of immunosuppressants, i.e. alkylating agents (cyclophosphamide), folic acid (methotrexate) and purine (azathioprine) antagonists. We will also talk about the history of cyclosporin A, the first "selective" immunosuppressive agent, and that of some immunoactive drugs used more recently in rheumatology, such as mycophenolate mofetil, dapson and thalidomide, is briefly described.
Sujet(s)
Allergie et immunologie/histoire , Antirhumatismaux/histoire , Immunosuppresseurs/histoire , Rhumatismes/traitement médicamenteux , Agents alcoylants/histoire , Agents alcoylants/usage thérapeutique , Antimétabolites/histoire , Antimétabolites/usage thérapeutique , Antirhumatismaux/usage thérapeutique , Ciclosporine/histoire , Ciclosporine/usage thérapeutique , Antifoliques/histoire , Antifoliques/usage thérapeutique , Rejet du greffon/prévention et contrôle , Histoire du 20ème siècle , Histoire du 21ème siècle , Humains , Immunosuppresseurs/classification , Immunosuppresseurs/usage thérapeutique , Acide mycophénolique/analogues et dérivés , Acide mycophénolique/histoire , Acide mycophénolique/usage thérapeutique , Thalidomide/effets indésirables , Thalidomide/histoire , Thalidomide/usage thérapeutiqueRÉSUMÉ
This article provides a perspective on the immediate and follow-up results of the COBRA trial that compared the combination of step-down prednisolone, methotrexate and sulfasalazine with sulfasalazine monotherapy in early rheumatoid arthritis (RA). The combination provided immediate relief of symptoms and signs of RA, but the clinical benefit compared to monotherapy appeared mostly dependent on low-dose glucocorticoid therapy that was mandatorily discontinued after 28 weeks. Strong benefit was apparent in the slowing of joint damage progression, and this effect persisted for over 10 years despite uncontrolled therapy after the trial period. In the trial toxicity of COBRA was less than monotherapy, and long-term safety of the regimen was comparable to regimens that do not include glucocorticoids. COBRA was the first study to validate the 'reverse-pyramid' concept in RA, and helped to establish the idea of a window of opportunity where the prognosis of RA may be altered with early and intensive therapy. Subsequent studies have shown COBRA is feasible in practice, acceptable to patients, and has efficacy similar to the combination of TNF inhibition and high-dose methotrexate, at a fraction of the cost.
Sujet(s)
Antirhumatismaux/administration et posologie , Polyarthrite rhumatoïde/traitement médicamenteux , Glucocorticoïdes/administration et posologie , Prednisolone/administration et posologie , Essais contrôlés randomisés comme sujet/histoire , Antirhumatismaux/histoire , Polyarthrite rhumatoïde/histoire , Association de médicaments , Glucocorticoïdes/histoire , Histoire du 20ème siècle , Humains , Prednisolone/histoire , Essais contrôlés randomisés comme sujet/méthodesRÉSUMÉ
The discovery and subsequent therapeutic use of glucocorticoids, which took 30 years, was stimulated by clinical observation and achieved by persistent investigation. Early reports of the potential of glucocorticoids to modify the underlying course of rheumatoid arthritis (RA) were overshadowed by pharmaceutical innovations with symptom relieving non-steroidal anti-inflammatory drugs (NSAIDs), and it was not until 1995 that clear-cut evidence of a powerful glucocorticoid disease-modifying action was published as the Arthritis Research Campaign Low-dose Glucocorticoid Study. This review reports how the study came to be designed and implemented, adds some additional information from the study not previously published, and considers the subsequent impact of the 1995 paper. Eighty years after Hench and colleagues made their first suggestion of benefit the UK National Health Service suggested all patients newly diagnosed with RA should have early access to glucocorticoid treatment.
Sujet(s)
Antirhumatismaux/histoire , Polyarthrite rhumatoïde/histoire , Essais cliniques comme sujet/histoire , Glucocorticoïdes/histoire , Antirhumatismaux/usage thérapeutique , Polyarthrite rhumatoïde/traitement médicamenteux , Glucocorticoïdes/administration et posologie , Histoire du 20ème siècle , Histoire du 21ème siècle , HumainsRÉSUMÉ
The treatment of rheumatoid arthritis traditionally includes symptomatic drugs, showing a prompt action on pain and inflammation, but without any influence on disease progression, and other drugs that could modify the disease course and occasionally induce clinical remission (DMARDs or disease modifying anti-rheumatic drugs). This review describes the historical steps that led to the use of the main DMARDs in rheumatoid arthritis, such as gold salts, sulphasalazine, chloroquine and hydroxychloroquine, D-penicillamine, and other immunoactive drugs, including methotrexate, azathioprine, cyclosporin and leflunomide. The historical evolution of use of these drugs is then discussed, including the strategy of progressive ("therapeutic pyramid") or of more aggressive treatment, through the simultaneous use of two or more DMARDs ("combination therapy").
Sujet(s)
Antirhumatismaux/histoire , Polyarthrite rhumatoïde/histoire , Anticorps monoclonaux/usage thérapeutique , Antirhumatismaux/classification , Antirhumatismaux/pharmacologie , Antirhumatismaux/usage thérapeutique , Polyarthrite rhumatoïde/traitement médicamenteux , Association de médicaments , Europe , Histoire du 16ème siècle , Histoire du 18ème siècle , Histoire du 19ème siècle , Histoire du 20ème siècle , Histoire du 21ème siècle , Histoire médiévale , Humains , Immunosuppresseurs/histoire , Immunosuppresseurs/pharmacologie , Immunosuppresseurs/usage thérapeutique , Facteur de nécrose tumorale alpha/antagonistes et inhibiteursRÉSUMÉ
The pharmacological treatment of pain has very ancient origins, when plant-derived products were used, including mandrake extracts and opium, a dried latex obtained from Papaver somniferum. In the XVI and XVII centuries opium came into the preparation of two compounds widely used for pain relief: laudanum and Dover's powder. The analgesic properties of extracts of willow bark were then recognized and later, in the second half of the XIX century, experimental studies on chemically synthesized analgesics were planned, thus promoting the marketing of some derivatives of para-amino-phenol and pyrazole, the predecessors of paracetamol and metamizol. In the XX century, nonsteroidal anti-inflammatory drugs were synthesized, such as phenylbutazone, which was initially considered primarily a pain medication. The introduction on the market of centrally acting analgesics, such as tramadol, sometimes used in the treatment of rheumatic pain, is quite recent.
Sujet(s)
Analgésiques/histoire , Antirhumatismaux/histoire , Phytothérapie/histoire , Analgésiques/usage thérapeutique , Anti-inflammatoires non stéroïdiens/histoire , Anti-inflammatoires non stéroïdiens/usage thérapeutique , Antirhumatismaux/usage thérapeutique , Europe , Histoire du 16ème siècle , Histoire du 17ème siècle , Histoire du 18ème siècle , Histoire du 19ème siècle , Histoire du 20ème siècle , Histoire ancienne , Histoire médiévale , Humains , Stupéfiants/histoire , Stupéfiants/isolement et purification , Stupéfiants/usage thérapeutique , Douleur/traitement médicamenteux , Extraits de plantes/histoire , Extraits de plantes/usage thérapeutique , Rhumatismes/traitement médicamenteuxRÉSUMÉ
The introduction of biological agents has been a major turning-point in the treatment of rheumatic diseases, particularly in rheumatoid arthritis. This review describes the principle milestones that have led, through the knowledge of the structure and functions of nucleic acids, to the development of production techniques of the three major families of biological agents: proteins, monoclonal antibodies and fusion proteins. A brief history has also been traced of the cytokines most involved in the pathogenesis of inflammatory rheumatic diseases (IL-1 and TNF) and the steps which have led to the use of the main biological drugs in rheumatology: anakinra, infliximab, adalimumab, etanercept and rituximab.
Sujet(s)
Antirhumatismaux/histoire , Facteurs biologiques/histoire , Rhumatismes/histoire , Rhumatologie/histoire , Anticorps monoclonaux/histoire , Anticorps monoclonaux/usage thérapeutique , Antirhumatismaux/usage thérapeutique , Facteurs biologiques/usage thérapeutique , Cytokines/antagonistes et inhibiteurs , Cytokines/physiologie , ADN/histoire , ADN recombiné/histoire , Code génétique , Histoire du 19ème siècle , Histoire du 20ème siècle , Histoire du 21ème siècle , Humains , Thérapie moléculaire ciblée/histoire , Prix Nobel , Rhumatismes/traitement médicamenteuxRÉSUMÉ
The history of the rheumatologic use of methotrexate until the 1990s will be reviewed, beginning with its pharmacology, with the focus on rheumatoid arthritis (RA). The insufficient availability of cortisone in the 1950s as well as the early recognition of its potential toxicity stimulated searches for alternative anti-inflammatory drugs. Two related derivatives of folic acid, aminopterin and amethopterin (MTX,) were found to give rapid symptomatic relief in cases of psoriasis vulgaris and psoriatic arthritis. For several years MTX was used primarily to treat psoriasis, and the dermatologic treatment protocols came to be used by rheumatologists. Giving MTX weekly rather than daily was found to diminish the risk of toxic effects. MTX became favoured over cyclophosphamide because of its lack of carcinogenicity, and although azathioprine lacked the hepatotoxicity of MTX, its anti-rheumatic effects were considered to be somewhat weaker. Although trials of MTX for the treatment of severe RA began in the 1960s, the first placebo-controlled study of MTX in RA was reported in 1985 and a comparison with Myochrysine in 1987. MTX has replaced gold compounds because it has been found to be more rapidly effective and better tolerated. The mechanisms of its anti-rheumatic effects remain incompletely explained, as are explanations of instances of its failure. Its recent use in combination with anti-TNFα agents appears to be another therapeutic advance.
Sujet(s)
Antirhumatismaux/usage thérapeutique , Polyarthrite rhumatoïde/traitement médicamenteux , Produits biologiques/usage thérapeutique , Méthotrexate/usage thérapeutique , Facteur de nécrose tumorale alpha/antagonistes et inhibiteurs , Antirhumatismaux/effets indésirables , Antirhumatismaux/histoire , Polyarthrite rhumatoïde/histoire , Polyarthrite rhumatoïde/immunologie , Produits biologiques/effets indésirables , Produits biologiques/histoire , Association de médicaments , Médecine factuelle , Histoire du 20ème siècle , Humains , Méthotrexate/effets indésirables , Méthotrexate/histoire , Résultat thérapeutiqueRÉSUMÉ
The development of methotrexate (MTX) as a therapy for rheumatoid arthritis (RA) evolved initially from positive case reports, uncontrolled case series and then several decades later placebo controlled studies followed by active comparator studies. These studies established MTX as a major therapy for RA. The importance of MTX in the treatment paradigm has only been enhanced over the past decade by the increased efficacy observed when small molecules and biologics are added to MTX. Since the first randomised studies were performed in the 1980s, MTX has now become the most well-studied disease modifying therapy to date and the most popular drug worldwide in the treatment of RA. This chapter will review the history of the development of MTX in RA.
Sujet(s)
Antirhumatismaux/usage thérapeutique , Polyarthrite rhumatoïde/traitement médicamenteux , Essais cliniques comme sujet , Médecine factuelle , Méthotrexate/usage thérapeutique , Antirhumatismaux/histoire , Polyarthrite rhumatoïde/histoire , Essais cliniques comme sujet/histoire , Médecine factuelle/histoire , Histoire du 20ème siècle , Humains , Méthotrexate/histoire , Résultat thérapeutiqueRÉSUMÉ
In this chapter, we review the use of DMARDs in several clinical RA cohorts and databases between the 1970s and the 2000s. The DMARD profile in the QUEST-RA database provides an overview of clinical use of MTX in recent years in 25 countries. The data show that (I) MTX is currently the most frequently used DMARD in RA, and (II) that this development has taken about 20 years to emerge.
Sujet(s)
Antirhumatismaux/usage thérapeutique , Polyarthrite rhumatoïde/traitement médicamenteux , Méthotrexate/usage thérapeutique , Antirhumatismaux/histoire , Polyarthrite rhumatoïde/histoire , Bases de données comme sujet , Utilisation médicament , Revue des pratiques de prescription des médicaments , Médecine factuelle , Histoire du 20ème siècle , Histoire du 21ème siècle , Humains , Méthotrexate/histoire , Résultat thérapeutiqueRÉSUMÉ
The chemical advances of the 20th century led to the synthesis of non steroidal anti-inflammatory drugs (NSAIDs), beginning from phenylbutazone and indomethacin and continuing with other new drugs, including ibuprofen, diclofenac, naproxen, piroxicam and, more recently, the highly selective COX-2 inhibitors (coxibs). This progress derived from the discovery of the mechanism of action of these drugs: the inhibition of synthesis of prostaglandins due to the cycloxigenase enzyme system, according to the experimental contributions of John R. Vane.